Glenmark Life Sciences Ltd - 543322 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March 2024
Please find enclosed herewith Certificate from Practicing Company Secretary under Regulation 40(9) of the SEBI (LODR) Regulations, 2015 for the financial year ended 31st March 2024 Glenmark Life Sciences Ltd - 543322 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March 2024
Please find enclosed Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the financial year ended 31st March 2024 Glenmark Life Sciences Ltd - 543322 - Disclosure Pursuant To Regulation 31A Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached herewith Disclosure pursuant to Regulation 31A of SEBI (LODR) Regulations, 2015 Glenmark Life Sciences Ltd - 543322 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Glenmark Pharmaceuticals Ltd Glenmark Life Sciences Ltd - 543322 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 13, 2024 for Glenmark Pharmaceuticals Ltd Glenmark Life Sciences Ltd - 543322 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nirma Limited acquires majority stake in Glenmark Life Sciences Glenmark Life Sciences Ltd - 543322 - Disclosure Pursuant To Regulation 30(7) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure pursuant to Regulation 30(7) of the SEBI (LODR) Regulations is attached. Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please enclosed find herewith copy of the Investor Presentation. Glenmark Life Sciences Ltd - 543322 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Glenmark Pharmaceuticals Ltd